Financial

Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE...

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) --...

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processingBERKELEY, Calif. and MAINZ, Germany, Nov....

AlayaCare Named One of Canada’s Enterprise–Industry Leaders Winners in Deloitte’s Technology Fast 50(TM) Program and Deloitte North American Technology Fast 500(TM) Program Winners for 2023

Advanced Health Intelligence Signs Binding Term Sheet with Electronic Medical Record and Global Personal Health Record Company OneClinic for Vietnam

HighlightsAHI signs binding term sheet with OneClinic, an electronic medical record (EMR) and personal health record (PHR) supplier for Vietnam.OneClinic...

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezolizumab...

Advanced Health Intelligence to provide Biometric Health Screening in new Collaboration between Bearn and OnCore Innovations Inc.

HighlightsAHI partner Bearn LLC signs new collaboration with OnCore Innovations Inc.AHI biometrics to be used in Bearn and OnCore platform.OnCore...

error: Content is protected !!